The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?
Abstract
Increasing attention is being directed towards the role of the serotonergic system in the neurochemistry of schizophrenia and antipsychotic drug treatment. This review considers the 5-HT1A receptor in this context. In patients with schizophrenia, the majority of post-mortem studies have reported increases in 5-HT1A receptor density in the prefrontal cortex in the approximate range 15–80%. Although the pathophysiological significance of this finding is unclear, given the location of a major proportion of these receptors on pyramidal cells, it may reflect an abnormal glutamatergic network. In terms of drug treatment, 5-HT1A agonists clearly display anticataleptic activity in rats. In addition, 5-HT1A agonists consistently increase dopamine release in the prefrontal cortex in rodents, which is an effect that might be predicted to improve negative symptoms. 5-HT1A agonists augment classical neuroleptics in some rat models of antipsychotic action and may be capable of modulating the glutamatergic network therapeutically. Despite the encouraging preclinical data, there is a paucity of clinical studies of 5-HT1A agonist augmentation of neuroleptics in the treatment of schizophrenia. However, the clinical relevance may be clarified by the atypical antipsychotic drugs clozapine, quetiapine and ziprasidone which combine D2 receptor antagonism and 5-HT1A agonism. In conclusion, given the increased prefrontal 5-HT1A receptor density in the illness, and the anticataleptic activity of 5-HT1A agonists combined with their ability to evoke prefrontal dopamine release, there is now a sufficient rationale to examine thoroughly the role of the 5-HT1A receptor in schizophrenia and antipsychotic drug treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain
Burnet, P. W. J., Eastwood, S. L., Lacey, K., & Harrison, P. J. (1995) · Brain Research · doi:10.1016/0006-8993(95)00104-x · Cited by 283
Cited by
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
The role of serotonin receptors in the action of atypical antipsychotic drugs
Meltzer, H., & Massey, B. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.007 · Cited by 381
Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research
Parrott, A. C. (2001) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.351 · Cited by 344
Metadata
- Authors
- Bantick, R. A., Deakin, J. F. W., & Grasby, P. M.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2001-01
- Volume
- 15
- Issue
- 1
- Pages
- 37-46
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2130322124
- Cited by
- 214
- References
- 1
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? https://app.cochat.ai/papers/10.1177/026988110101500108
- The paper
- Bantick, R. A., Deakin, J. F. W., & Grasby, P. M. (2001). The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? Journal of Psychopharmacology. https://doi.org/10.1177/026988110101500108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.